Navigation Links
Mylan Receives Approval for Generic Version of Xalatan® Ophthalmic Solution
Date:4/4/2011

PITTSBURGH, April 4, 2011 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Latanoprost Ophthalmic Solution, 0.005%, the generic version of Pharmacia and Upjohn's Xalatan® Ophthalmic Solution, an eyedrop that lowers pressure in the eye.  

Mylan President Heather Bresch said: "We are very pleased to introduce this product to the market as it represents Mylan's first ophthalmic solution. This signifies a new internal development capability for the company, and we currently have in development a number of additional products in this important category."  

Latanoprost Ophthalmic Solution had U.S. sales of approximately $711 million for the 12 months ending Dec. 31, 2010, according to IMS Health. Mylan is shipping this product immediately.

Currently, Mylan has 168 ANDAs pending FDA approval representing $98.7 billion in annual sales, according to IMS Health. Forty-eight of these pending ANDAs are potential first-to-file opportunities, representing $25.9 billion in annual brand sales, for the 12 months ending June 30, 2010, according to IMS Health.

Mylan Inc. ranks among the leading generic and specialty pharmaceutical companies in the world and provides products to customers in more than 150 countries and territories. The company maintains one of the industry's broadest and highest quality product portfolios supported by a robust product pipeline; operates one of the world's largest active pharmaceutical ingredient manufacturers; and runs a specialty business focused on respiratory, allergy and psychiatric therapies. For more information about Mylan, please visit www.mylan.com. For more information about generic drugs, please visit www.ChoosingGenerics.com.


'/>"/>
SOURCE Mylan Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Mylan Announces Exclusive Distribution Partnership with Humeca to Expand Burn and Wound Care Portfolio
2. Moodys Upgrades Mylan
3. Mylan Confirms First-to-File Patent Challenge Relating to Vivelle-Dot®
4. Mylan Receives Approval for Generic Version of Neurontin® Capsules
5. Mylan Launches First Generic Version of Vfend® Tablets
6. Mylan Receives Approval for First-to-File Generic Sular® Extended-Release Tablets
7. Mylans Matrix Obtains License for Promising HIV/AIDS Treatment
8. Mylan Announces Lipitor® Settlement Agreement
9. Mylan Announces Caduet® Settlement Agreement
10. Mylans Matrix Receives Approval for Generic Version of Protonix® Delayed-release Tablets
11. Mylans Matrix Receives Tentative FDA Approval Under PEPFAR for Lamivudine and Zidovudine Tablets, 30 mg/60 mg
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... Mass. , February 23, 2017 - ...   ... Honoring Rare Disease Day Open to All at http://www.shire.com/RareCount   ... today announced the launch of ,Rare Count, in honor of Rare ... diseases, which equates to nearly one in 20 global citizens. It ...
(Date:2/22/2017)... , Feb. 22, 2017 IRIDEX Corporation (Nasdaq: ... release financial results for the fourth quarter and 2016 ... 2017.  The Company,s management team will host a corresponding ... p.m. ET. Investors interested in listening to ... 707-0665 for domestic callers or (703) 326-3030 for international ...
(Date:2/22/2017)... , Feb. 22, 2017 Summary ... deals and agreements entered into by the worlds leading ... Description The Global Spinal Cord Partnering Terms ... to partnering deals and agreements entered into by the ... partnering deals - Top deals by value ...
Breaking Medicine Technology:
(Date:2/22/2017)... ... February 22, 2017 , ... The Waismann Method® is providing ... who have recently fallen victim to America’s opioid epidemic. Now, opiate dependent individuals can ... they are free from the shame, stigma, and harmful labeling believed to ...
(Date:2/22/2017)... TX (PRWEB) , ... February ... ... Risk Adjustment solution leverages advanced data analytics to accurately understand each Medicare ... proper reimbursement for a given population. This new solution helps transform the ...
(Date:2/22/2017)... ... February 22, 2017 , ... ... absorption cannabidiol (CBD) serum, “NANOCALM 300” Microemulsified Hemp Extract. This premier nanoemulsified ... from the mouth into the bloodstream. Far outpacing the absorption speed ...
(Date:2/22/2017)... ... February 22, 2017 , ... Becker’s Spine Review, ... is featuring Michigan neurosurgeon Jay Jagannathan, M.D., as a “Spine Surgeon to Know.” ... of neurosurgeons in Michigan performing minimally invasive back surgery that often results in ...
(Date:2/22/2017)... ... , ... The SeniorCare Investor will host an important webinar— Seniors Housing M&A: ... 1:00 PM ET. A recording of the webinar will also be made available following ... you want to find out what really happened in the seniors housing and care ...
Breaking Medicine News(10 mins):